ClinicalTrials.gg

Program

AR882

A development code. Also written as “AR882 75 mg”, “AR882 50 mg” and “AR882 Dose 1”.

Its studies are mostly in Arthritis, Gouty · Hyperuricemia · Renal Insufficiency, led by 2 companies.

Furthest: phase 3, since May 28, 202410 company-led studies, 2 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Swedish Orphan Biovitrum91 open or runningphase 3since May 28, 2024Oct 25, 2019Nov 2026phase 2 · NCT07116746
Guangzhou Ruianbo Pharmaceutical Technology11 open or runningphase 3since Sep 17, 2024Sep 17, 2024none ahead

Also a collaborator on its studies: iqvia-pty-ltd and celerion.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 25, 2019First study: phase 2 study in HyperuricemiaNew to Swedish Orphan BiovitrumSwedish Orphan Biovitrum · NCT04155918 · 30 enrolled · New Zealand
  2. Mar 10, 2020Phase 1 study in Healthy VolunteersSwedish Orphan Biovitrum · NCT04347005 · 64 enrolled · Australia
  3. Aug 6, 2020Phase 1 study in Healthy VolunteersSwedish Orphan Biovitrum · NCT04508426 · 6 enrolled · United States
  4. Nov 18, 2020Phase 1 study in Renal InsufficiencySwedish Orphan Biovitrum · NCT04646889 · 46 enrolled · United States, New Zealand
  5. Oct 20, 2021Phase 2 study in GoutSwedish Orphan Biovitrum · NCT05119686 · 140 enrolled · United States, Australia, Taiwan
  6. Feb 15, 2022Phase 2 study in GoutSwedish Orphan Biovitrum · NCT05253833 · 42 enrolled · United States, New Zealand, Taiwan
  7. May 28, 2024Phase 3 study in GoutSwedish Orphan Biovitrum · NCT06439602 · 818 enrolled · United States, Australia, Hong Kong and more
  8. Sep 17, 2024Guangzhou Ruianbo Pharmaceutical Technology's first study: phase 3 study in HyperuricemiaNew to Guangzhou Ruianbo Pharmaceutical TechnologyGuangzhou Ruianbo Pharmaceutical Technology · NCT06603142 · 636 enrolled · China
  9. Feb 21, 2025Phase 3 study in GoutSwedish Orphan Biovitrum · NCT06846515 · 866 enrolled · United States
  10. Aug 7, 2025Phase 2 study in GoutSwedish Orphan Biovitrum · NCT07116746 · 15 enrolled · United States

Ahead

  1. Nov 2026Primary completion: phase 2 study in GoutSwedish Orphan Biovitrum · NCT07116746

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07116746Gout · United States2Active, not recruitingSwedish Orphan BiovitrumNov 202615
NCT06846515Gout · United States3CompletedSwedish Orphan BiovitrumAug 31, 2026866
NCT06603142Hyperuricemia · China3Active, not recruitingGuangzhou Ruianbo Pharmaceutical TechnologyApr 2026636
NCT06439602Gout · United States, Australia, Hong Kong and more3CompletedSwedish Orphan BiovitrumMar 20, 2026818
NCT05253833Gout · United States, New Zealand, Taiwan2CompletedSwedish Orphan BiovitrumAug 13, 202442
NCT05119686Gout · United States, Australia, Taiwan2CompletedSwedish Orphan BiovitrumNov 17, 2022140
NCT04646889Renal Insufficiency · United States, New Zealand1CompletedSwedish Orphan BiovitrumJun 27, 202246
NCT04508426Healthy Volunteers · United States1CompletedSwedish Orphan BiovitrumAug 12, 20206
NCT04347005Healthy Volunteers · Australia1CompletedSwedish Orphan BiovitrumJul 31, 201964
NCT04155918Hyperuricemia · New Zealand2CompletedSwedish Orphan BiovitrumSep 3, 202030

How it is read

Names in the registry

  • “AR882 75 mg”, 3 entries
  • “AR882 50 mg”, 2 entries
  • “AR882 Dose 1”, 2 entries
  • “AR882 Dose 2”, 2 entries
  • “AR882 25MG”, 1 entry

Codes read as this program: AR882.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.